DSM sales, EBITDA slightly down in 2Q
date:Aug 08, 2014
rall, sales were down 5%, which the company attributed to price/mix (2%) and currency exchange (3%).

DSM delivered improved results versus the first quarter, despite persistent currency headwinds, said Feike Sijbesma, CEO/chairman of the DSM Managing Board. Performance Materials saw continued positive momentum in a number of end-markets, whereas Polymer Intermediates has seen weaker business conditions for caprolactam. Market conditions in Nutrition have shown some improvement with good Animal
2/4 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/15 01:16